Smithkline Corporation

Smithkline Beecham Corporation

Smithkline Beckman Corporation

Other

Anormed, Inc.

John G Gleason

Ralph F Hall

Kenneth G Holden

William F Huffman

David T Hill

Thomas Wen-Fu Ku

Carl D Perchonock

Joseph Weinstock

Paul E Bender

Katherine L Widdowson

Nelson C Yim

Thomas F Buckley

Charles M Kinzig

James S Frazee

Deborah Lynne Bryan

Nabil Hanna

John F Newton

Jerry Leroy Adams

Juan I Luengo

John Duncan Elliott

James Martin Samanen

Irene Nijole Uzinskas

Henry M Sarau

Judith Hempel

Joanne Smallheer

Deborah Lynn Bryan

Kazys A Razgaitis

Siegfried B Christensen, Iv

Cornelia Jutta Forster

Jack Dale Leber

Brian W Metcalf

Ivan Lantos

Stephen F Miller

Don Edgar Griswold

Russell Donovan Cousins

Alison Mary Badger

Susan C Shilcrat

Kathleen A Phipps

Gerald C Simolike

Benjamin Blank

Faida E Ali

Seymour Mong

Sylvia T Hoffstein

Dimeric cell-surface receptors in a subject are agonized by administering a metal chelated dimeric cell-surface receptor ligand formed by chelating a receptor binding moiety with a metal ion such as zinc, or by co-administering the receptor binding moiety and the metal ion. The binding moiety is a small organic molecule having a molecular weight of from about 100 to about 850, and metal chelation may form a symmetrical multimer such as a dimer of the receptor binding moiety. An example is bis&lcub;2,5-bis&lsqb;2-benzimidazolylimino&rsqb;-3a,6a-bis(2-pyridyl)-1,2,3,3a,4,5,6,6a-octahydroimidazo&lsqb;4,5-d&rsqb;imidazole-N,N&prime;&rcub;-zinc(II). Dimeric cell surface receptors include granulocyte colony-stimulating factor, erythropoeitin receptor, macrophage-colony-stimulating factor, growth hormone receptor, thrombopoietin receptor, interferon alpha receptor, interferon beta receptor, tyrosine kinase receptor, insulin receptor and leptin receptor. A pharmaceutical composition containing a carrier and the ligand or the binding moiety and the metal ion separately can be used to enhance leukocyte production and to treat bacterial and fungal infections.

Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal

Novel compounds useful in the treatment of Interleukin-8 mediated diseases, and methods of using them are disclosed.

IL-8 receptor antagonists

The invention describes zinc chelated dimeric cell-surface receptor ligands, pharmaceutical compositions containing these compounds, methods of using these compounds as agonist of dimeric cell-surface receptors. Novel processes used in preparing the compounds are also described. Further, the invention describes novel receptor binding moieties of the zinc chelated cell-surface receptor ligands.

Metal complexes

This invention relates to novel compounds, pharmaceutical compositions comprising these compounds and their use in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

This invention relates to novel compounds of Formula (1), pharmaceutical compositions and their use in the treatment of disease states mediated by the chemokine, Interleukins-8 (IL-8).

The present invention relates to novel pyridine derivatives and compositions comprising them useful in the treatment of disease states mediated by the chemokine Interleukin-8.

Method of treating asthma

A mixture of beads from a combinatorial library is held in suspension either by inducing circulating flow of a liquid in a tapered vessel by rising air bubbles or by floating the beads at the interface between two immiscible liquids. Beads are selected individually from the suspension by drawing liquid into the tip of a needle having a circular opening smaller than the diameter of a bead. After a bead is captured on the tip of a needle, excess beads are jarred loose or washed away by flow of a solvent through a sheath surrounding the needle, and the needle is moved by a robotic manipulator to a well into which the bead is released.

Apparatus and process for arraying beads

Angiotensin II receptor antagonists having the formula: ##STR1## which are useful in regulating hypertension and in the treatment of congestive heart failure, renal failure, and glaucoma, pharmaceutical compositions including these antagonists, and methods of using these compounds to produce angiotensin II receptor antagonism in mammals.

Substituted imidazolyl-alkyethio-aldanoic acids

Endothelin receptor antagonists

Substituted imidazolyl-alkylthio-alkanoic acids

Cytokine inhibiting imidazole substituted hydroxamic acid derivatives

Substituted histidines

Novel compounds of Formulas (I) and (II) ##STR1## are described herein. These compounds inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase IV.

4-phenyl-1,2-cyclohexyl derivatives and anti-inflammatory compositions

Substituted histidines having angiotension II receptor antagonist

Growing community of inventors

Delran, NJ, United States of America

John G Gleason